GlassScriptPhysician profile
Drew A Thompson
NPI 1962010785
$338.24
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $338.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $50.96 | 2021 | |
| Amarin Pharma, INC. | $48.67 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $44.31 | 2021 | |
| Abbvie INC. | $38.64 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $34.67 | 2021 | |
| Novo Nordisk INC | $28.20 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $27.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.00 | 2021 | |
| Genentech USA, INC. | $18.44 | 2021 | |
| Glaxosmithkline, LLC. | $14.09 | 2021 | |
| Amgen INC. | $12.97 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.